Anthony J. Guzzo - 19 Jan 2022 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role: VP, Chief Accounting Officer
Signature: /s/ Larry Miller, Attorney-in-Fact for Anthony J. Guzzo
Issuer symbol: PHAT
Transactions as of: 19 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 21 Jan 2022, 17:49:43 UTC
Previous filing: 11 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHAT	Common Stock	Award	$0	+6,000	+250%	$0.000000	8,399	19 Jan 2022	Direct	F1, F2
holding	PHAT	Common Stock						464	19 Jan 2022	by 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PHAT	Stock Option (Right to Buy)	Award	$0	+30,000		$0.000000	30,000	19 Jan 2022	Common Stock	30,000	$15.21	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2	Includes 2,399 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2021 and January 2022.
F3	The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.